Funding news · Oct 1, 2026
TriGemX Bio Raises $94M Series C+ Led by The Column Group for Phase 3 Migraine Program
TriGemX Bio Secures $94M Series C+ Financing
TriGemX Bio, a New York City-based biotechnology company developing medicines for the treatment of migraine, has raised $94 million in Series C+ funding. The round was led by The Column Group, with participation from Viking Global Investors and TCGX.
What the Company Does
TriGemX Bio — formerly known as Kallyope — is focused on migraine therapeutics, leveraging insights into neural signaling pathways. The company's name references the trigeminal ganglion, a migraine-relevant neural structure where TRPM8 is expressed.
Its lead program, elismetrep, is a novel oral TRPM8 channel blocker in Phase 3 trials for the acute treatment of migraine. Results from the first Phase 3 trial are anticipated in mid-2027.
The Round at a Glance
- Company: TriGemX Bio
- Round type: Series C+
- Amount raised: $94,000,000 USD
- Funding date: October 1, 2026
- Lead investor: The Column Group
- Additional investors: Viking Global Investors, TCGX
Why It Matters
The Series C+ extends the company's runway as it advances elismetrep through late-stage clinical development. With a Phase 3 readout expected in mid-2027, the financing positions TriGemX Bio to execute on its acute migraine program during a capital-intensive period for clinical-stage biotechs.
The involvement of The Column Group as lead, alongside Viking Global Investors and TCGX, signals continued investor conviction in the TRPM8 mechanism and the company's neural signaling approach to migraine treatment.
About TriGemX Bio
TriGemX Bio is headquartered in New York City and develops medicines for migraine by drawing on insights into neural signaling pathways. Its lead asset, elismetrep, is an oral TRPM8 channel blocker currently in Phase 3 trials for acute migraine treatment.
Looking Ahead
The key near-term milestone for the company is the first Phase 3 trial readout for elismetrep, expected in mid-2027. The Series C+ capital is positioned to support the company through that period.